Media and Communications

News

NA

Monday, January 26, 2015
Teva Receives FDA Approval for First Generic Nexium® Delayed-Release Capsules in the United States

JERUSALEM--(BUSINESS WIRE)--Jan. 26, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the Food and Drug Administration (FDA) approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States. Teva is preparing to launch the product in the near future. Nexium Delayed-Release Capsules, marketed by AstraZeneca, had annual sales of approximately $6 billion in the United States, according to IMS data as of November 2014. About Teva Read More »

Thursday, January 15, 2015
Teva to Report Fourth Quarter 2014 Financial Results on February 5, 2015

JERUSALEM--(BUSINESS WIRE)--Jan. 15, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will release its fourth quarter 2014 financial results on Thursday, February 5, 2015 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its fourth quarter 2014 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minute Read More »

Thursday, January 08, 2015
Teva to Present at the 33rd Annual J.P. Morgan Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Jan. 8, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the 33rd Annual J.P. Morgan Healthcare Conference. Erez Vigodman, President & CEO will present on Tuesday, January 13, 2015 at 3:30 PM PST. What:     Teva Presentation at the 33rd Annual J.P. Morgan Healthcare Conference Read More »

Monday, December 22, 2014
Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

JERUSALEM--(BUSINESS WIRE)--Dec. 22, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Goldman Sachs Healthcare CEOs Unscripted Conference. Erez Vigodman, President & CEO will present on Tuesday, January 6, 2015 at 10:15 AM EST.     What: Teva Presentation at the Goldman Sachs Healthcare CEOs U Read More »

Friday, December 19, 2014
Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis

First Waterless Nasal Allergy Spray Approved for Children as Young as Four Years of Age JERUSALEM--(BUSINESS WIRE)--Dec. 19, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved QNASL® (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis (AR) in children 4-11 years of age. QNASL® 40 mcg is a lower dose formulation of QNASL® Nasal Aerosol (80 mcg), a waterless (non-aqueous) intranasal Read More »

Thursday, December 11, 2014
Teva Provides 2015 Business Outlook

JERUSALEM--(BUSINESS WIRE)--Dec. 11, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) provides its current outlook for non-GAAP financial performance for the year ending December 31, 2015. In an effort to enhance investor understanding of the Company’s business performance, and to provide more clarity and transparency regarding its projections for 2015, the following assumptions will apply to the 2015 non-GAAP financial outlook: Compared to 2014, foreign exchange rate fluctuations are expected to Read More »

Monday, December 01, 2014
Teva Announces Launch of Generic Exforge HCT® Tablets in the United States

JERUSALEM--(BUSINESS WIRE)--Dec. 1, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Exforge HCT® (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets in the United States. Teva was first to file, opening the generic market for the product, as well as making the product eligible for 180 days of marketing exclusivity. Exforge HCT ® (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets, marketed by Novartis Pharmaceuticals, had annual sales of approximately $1 Read More »

Wednesday, November 26, 2014
Prof. Yitzhak Peterburg Elected Chairman of Teva’s Board of Directors

Dr. Sol J. Barer joins the Board JERUSALEM--(BUSINESS WIRE)--Nov. 26, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the Board of Directors has elected Professor Yitzhak Peterburg as Chairman, effective January 1, 2015. Prof. Peterburg, a member of the Board since 2012 and from 2009-2010, will succeed Dr. Phillip Frost, who previously announced plans to step down as Chairman by the end of the year. Dr. Frost has also informed the Board that he will not stand for reelection as a director at the upco Read More »

Friday, November 07, 2014
Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

Late Stage Data from Multiple Studies Showcase Safety and Efficacy Profile JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia Read More »

Friday, November 07, 2014
Teva Presents Positive Safety and Efficacy Data for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis

Late Stage Data to be Presented at ACAAI 2014 JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL® (beclomethasone dipropionate) Nasal Aerosol 80 μg/day in children 4-11 years of age with perennial – or “year round” – allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhiniti Read More »

​​​